ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1441

Epstein Barr Virus CD40 Functional Mimic Latent Membrane Protein-1 Drives Cellular Molecular Mimicry in the Presence of Epstein Barr Virus Nuclear Antigen-1 in a Novel Murine Model of Lupus-Like Disease

Melissa E. Munroe1, Jourdan R. Anderson2, Timothy F. Gross3, Laura L. Stunz4, Gail A. Bishop4 and Judith A. James5, 1Arthritis and Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 2Arthritis & Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 3Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 4The University of Iowa, Iowa City, IA, 5Oklahoma Medical Research Foundation; University of Oklahoma Health Sciences Center, Oklahoma City, OK

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Animal models, cell biology, cytokines, immune response and systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Animal Models

Session Type: Abstract Submissions (ACR)

Background/Purpose: Immune dysregulation underlies the complex pathogenesis of SLE. Infection with Epstein Barr Virus (EBV) and expression of latent protein Epstein Barr Virus Nuclear Antigen-1 (EBNA-1, a humoral molecular mimic with SLE associated autoantigens) has been linked with SLE. Acting in an enhanced and sustained manner, the Latent Membrane Protein-1 (LMP1, another major EBV latent protein) cytoplasmic tail is necessary and sufficient as a functional mimic of the TNF Receptor, B cell stimulatory molecule CD40. Mice were created expressing a transgene (Tg) for the chimeric molecule mCD40-LMP1 (containing the cytoplasmic tail of LMP1) and bred onto a CD40-/- background to remove endogenous CD40. The mCD40-LMP1 Tg mice have normal T-dependent antibody responses, spontaneous germinal center formation, and autoantibodies by 2-3 months of age. However, no overt autoimmune disease or early death develops in this model. This study evaluates the nature of the immune response to EBNA-1 in mCD40-LMP1 Tg mice and whether the addition of a molecular mimic in this model could accelerate lupus pathogenesis. 

Methods: mCD40-LMP1 Tg, full length mCD40 Tg (Tg strain control), and congenic C57Bl/6 (B6) mice (8-12 weeks of age) were immunized (in CFA) and boosted (in IFA) with EBNA-1 over an 8-week course. Saline/adjuvant and naïve control mice were also employed. Draining lymph node cells were cultured in antigen-recall assays stimulated with EBNA-1, the EBNA-1 antigenic epitope PPPGRRP (GRR), the cross-reactive autoantigen Sm, or the Sm antigenic epitope PPPGMRPP (GMR). Proliferation was measured by 3H-Thymidine incorporation and culture supernatant cytokines by xMAP multiplex assay. Serum antibodies to EBNA-1, autoantibodies, and BUN and creatinine levels were also assessed.

Results: Anti-EBNA-1 antibody levels are comparable in mCD40-LMP1 Tg, mCD40 Tg and B6 congenic mice. EBNA-1 specific proliferative and inflammatory cytokine responses, including IL-6, IL-17, IFN-γ, and TNF-α, are significantly enhanced (p < 0.0001) in mCD40-LMP1 Tg compared to mCD40 Tg, B6 mice, and adjuvant and naïve control mice. In addition, mCD40-LMP1 Tg mice immunized with EBNA-1 exhibit significantly enhanced cellular responses (p < 0.0001) to the EBNA-1 antigenic epitope GRR and cross-react to the autoantigen Sm, as well as its antigenic epitope GMR. The cross-reactive cellular response to GRR and Sm starts within 10 days post-immunization with EBNA-1 in mCD40-LMP1 Tg mice. Cross-reactivity to the Sm epitope GMR occurs within 4 weeks after initial immunization. Enhanced cellular immune dysregulation with EBNA-1 immunization in mCD40-LMP1 mice is accompanied by enhanced splenomegaly, increased serum BUN and creatinine levels, and elevated anti-dsDNA and ANA autoantibody levels (p <0.0001 compared to mCD40 Tg and B6 mice, p < 0.01 compared to adjuvant and naïve mCD40-LMP1 mice).

Conclusion: Mice Tg for mCD40-LMP1 exhibit enhanced cellular responses to EBNA-1. In the presence of LMP1, EBNA-1 induces cellular molecular mimicry to the SLE associated autoantigen Sm. These data suggest that expression of EBV latent proteins EBNA-1 and LMP1 may contribute to immune dysregulation that leads to pathogenic autoantigen-specific inflammation in lupus.


Disclosure:

M. E. Munroe,
None;

J. R. Anderson,
None;

T. F. Gross,
None;

L. L. Stunz,
None;

G. A. Bishop,
None;

J. A. James,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/epstein-barr-virus-cd40-functional-mimic-latent-membrane-protein-1-drives-cellular-molecular-mimicry-in-the-presence-of-epstein-barr-virus-nuclear-antigen-1-in-a-novel-murine-model-of-lupus-like-disea/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology